【News】Kringle Pharma, Inc. is approved for listing on the Tokyo Stock Exchange

Kringle Pharma, Inc., a company that develops pharmaceutical products based on Hepatocyte Growth Factor (HGF), was approved to be listed on Tokyo Stock Exchange Mothers on November 24, 2020. Kringle Pharma, Inc. is a company invested by CYBERDYNE Inc. and CEJ Fund (Cybernics Excellence Japan Fund 1 Investment Limited Partnership. It is operated by CYBERDYNE’s subsidiary CEJ Capital Co., Ltd. Kringle Pharma, Inc. is scheduled to be listed on December 28, 2020 and its ticker code will be 4884.

HGF (Hepatocyte Growth Factor)
HGF is a biological protein discovered in Japan as a factor that promotes the proliferation of mature hepatocytes. Subsequent studies have shown that it has a variety of physiological activities that play a role in the regeneration and protection of various tissues and organs, such as the promotion of cell motility, inhibition of cell death, induction of morphogenesis, antifibrosis, and angiogenesis, as well as cell proliferation. The non-clinical pharmacological effects of HGF on neuroprotection and axonal stretching as well as on spinal cord injury and amyotrophic lateral sclerosis (ALS) were demonstrated by Professor Hideyuki Okano and Professor Masaya Nakamura of the Department of Physiology and Orthopedics, Keio University of Medicine, and Professor Masashi Aoki of the Department of Neurology, Tohoku University. HGF is anticipated to be a new treatment method towards aforementioned neurological diseases.

About Kringle Pharma  https://www.kringle-pharma.com/en/
Kringle Pharma, Inc. was established as a pharmaceutical biotechnology venture company originating from Osaka University in December 2001 with the goal of developing and commercializing new bio medicines using HG. Currently the company uses HGF biological protein to develop following therapeutics.
１）Acute phase of spinal cord injury (phase III study underway)
２）ALS（Phase II study/investigator initiated clinical trial underway）
３）Vocal cord scarring (Phase I/II study/investigator initiated clinical trial completed)
４）Acute kidney injury (phase Ia and Ib studies completed)
In the treatment of spinal cord injury, reducing the extent of damage during the acute phase (secondary damage) is crucial for the subsequent recovery of function. Drug for spinal cord injury based on HGF protein being developed as therapeutics that can be administered to patients with spinal cord injury immediately after the injury and because of its great medical significance, early development of therapeutics is anticipated. The company is pursuing further development to bring HGF protein-based therapeutics as soon as possible.

Announcement by Kringle Pharma (available in Japanese only)
https://www.kringle-pharma.com/wp-content/uploads/2020/11/201124_上場承認（プレスリリース）.pdf